CommercialCoverageMedium impact
08.01.43p, Chimeric Antigen Receptor (CAR) Therapy
Independence Blue Cross·Oncology, Hematology·Medical Policy
Effective date
Feb 24, 2025
We identified it
Jun 19, 2026
Summary
Independence Blue Cross updated their medical necessity criteria for Chimeric Antigen Receptor (CAR) therapy, which is a specialized cancer treatment. The policy change affects coverage determinations for this advanced immunotherapy treatment.
Action Required
By February 24, 2025: Billing team must review updated medical necessity criteria for CAR therapy claims. Providers must ensure documentation meets new criteria requirements before submitting claims. Contact Independence Blue Cross for specific documentation requirements to avoid claim denials.